Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Exclusion Criteria

• •Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence or breast CIS.
• •In patients with a prior history of invasive malignancy, less than five years in complete remission.
• •Positive serology for HIV, hepatitis B or hepatitis C.
• •Significant co-morbid illness such as uncontrolled diabetes or active infection that would preclude treatment on this regimen.
• •Use of corticosteroids or other immunosuppression (if patient had been taking steroids, at least 2 weeks must have passed since the last dose).
• •Patients with organ allografts.
• •Uncontrolled hypertension (BP \>150/100 mmHg).
• •Proteinuria dipstick \> 3+ or ≥ 2gm/24 hours.
• •Urine protein:creatinine ratio ≥ 1.0 at screening.
• •Major surgery, open biopsy, significant traumatic injury within 28 days of starting treatment or anticipation of need for major surgical procedure during the course of the study.
• •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to starting treatment. Central venous catheter placements are permitted.
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to starting treatment.
• •Serious, non-healing wound, ulcer, or bone fracture.
• •History of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathy.
• •History of deep venous thrombosis, clinically significant peripheral vascular disease, or other thrombotic event.
• •Inability to comply with study and/or follow-up procedures.
• •Individuals with known history of glucose 6 phosphate deficiency are excluded from the trial (possible issue with HCQ tolerance).
• •Patients with previously documented macular degeneration or diabetic retinopathy are excluded from the trial.
• •Baseline EKG with QTc \> 470 msec (including subjects on medication). Subjects with ventricular pacemaker for whom QT interval is not measurable will be eligible on a case-by-case basis.